Nordwand Advisors’s Immuneering IMRX Stock Holding History

Nordwand Advisors’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,000	Closed	-$2.56K	–	155
2024 Q2	$2.56K	Buy	+2,000	New	+$3.29K	﹤0.01%	137

Other funds holding IMRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Southport Management Wilson, Wyoming $28.6M AUM 41.61% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Nordwand Advisors's IMRX Position: Q3 2024 in Review

Nordwand Advisors sold out of Immuneering (IMRX) in Q3 2024, closing a stake of 2,000 shares — an estimated $2.56K sold.

Nordwand Advisors first reported a position in IMRX in Q2 2024 and held it in 1 quarter. The position peaked at $2.56K in Q2 2024. 38 funds tracked by Wall St. Rank hold IMRX as of Q3 2024.

Nordwand Advisors reported no remaining Immuneering position as of Q3 2024 after selling out during the quarter.
Nordwand Advisors sold 2,000 Immuneering shares in Q3 2024, an estimated $2.56K.
Nordwand Advisors first reported a position in Immuneering in Q2 2024 and held it in 1 quarter.
Nordwand Advisors's Immuneering position peaked at $2.56K in Q2 2024.
38 funds tracked by Wall St. Rank held Immuneering as of Q3 2024.

Based on Nordwand Advisors's 13F filing for Q3 2024, filed 1 Nov 2024.